Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by Pandoraon Oct 14, 2021 1:43pm
195 Views
Post# 34006036

RE:RE:The offering -- Sedar

RE:RE:The offering -- Sedar

25 ADELAIDE STREET EAST SUITE 1900 TORONTO ONTARIO M5C 3A1
ENRICO MORETTI DESK: 416.867.8800 X203 CELL: 416.543.0729 EMAIL: ENRICO@BOYLECO.COM



FILED VIA SEDAR

October 13, 2021

Ontario Securities Commission
British Columbia Securities Commission
Alberta Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan



Dear Ladies and Gentlemen:

Re: Ventripoint Diagnostics Ltd. (the “Issuer”)
SEDAR Project No. 03282779
Final Short Form Prospectus dated October 13, 2021 (the “Prospectus”) under
National Instrument 44-101, Multilateral Instrument 11-102 and National Policy 11-
202


We refer to the Prospectus of the Issuer.

We hereby consent to the use of our firm name and to the reference to our opinion under the headings
“Eligibility for Investment” and “Legal Matters” of the Prospectus and to the use of our firm name on
page (iii) and under the heading “Interests of Experts” of the Prospectus.


We confirm that we have read the Prospectus and have no reason to believe that there are any
misrepresentations in the information contained in the Prospectus that are derived from our opinion
referred to above or that is within our knowledge as a result of the services we performed in connection
with such opinion.


Yours very truly,
Boyle & Co. LLP
<< Previous
Bullboard Posts
Next >>